Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | CFD | P00746 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1336728 | 1.00 | CACNA1B (0.41) | CACNA1BKCNH2SCN9AKMT2AL3MBTL1 | |
| SCHEMBL16498621 | 1.00 | CACNA1B (0.41) | CACNA1BKCNH2SCN9AKMT2AL3MBTL1 | |
| SCHEMBL66703 | 0.85 | NPC1 (0.45) | CACNA1BKCNH2KMT2A | |
| SCHEMBL66458 | 0.80 | KMT2A (0.53) | CACNA1BKCNH2SCN9AKMT2AL3MBTL1 | |
| SCHEMBL14367715 | 0.80 | KMT2A (0.53) | CACNA1BKCNH2SCN9AKMT2AL3MBTL1 | |
| SCHEMBL66495 | 0.80 | KMT2A (0.53) | CACNA1BKCNH2SCN9AKMT2AL3MBTL1 | |
| SCHEMBL65557 | 0.79 | NPC1 (0.44) | CACNA1BKCNH2KMT2AL3MBTL1 | |
| SCHEMBL1337446 | 0.78 | CACNA1B (0.53) | CACNA1BKCNH2 | |
| SCHEMBL1337445 | 0.78 | CACNA1B (0.53) | CACNA1BKCNH2 | |
| SCHEMBL66167 | 0.77 | CACNA1B (0.47) | CACNA1BKCNH2SCN9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | CACNA1B 5/4885KCNH2 24/4885SCN9A 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.